Compare ANIK & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANIK | ACOG |
|---|---|---|
| Founded | 1983 | 2000 |
| Country | United States | Canada |
| Employees | N/A | 71 |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 200.9M | 185.1M |
| IPO Year | 1996 | N/A |
| Metric | ANIK | ACOG |
|---|---|---|
| Price | $14.92 | $7.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $17.00 | $16.00 |
| AVG Volume (30 Days) | 59.7K | ★ 92.2K |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.16 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $112,819,000.00 | N/A |
| Revenue This Year | $5.98 | $139.22 |
| Revenue Next Year | $7.42 | $134.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.90 | $4.50 |
| 52 Week High | $16.49 | $10.14 |
| Indicator | ANIK | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 46.28 | 56.70 |
| Support Level | $13.88 | $5.27 |
| Resistance Level | $15.53 | $8.80 |
| Average True Range (ATR) | 0.65 | 0.56 |
| MACD | -0.13 | -0.08 |
| Stochastic Oscillator | 17.80 | 40.74 |
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.